Tideglusib, a non-ATP active GSK-3β antagonist, reduced tau phosphorylation, diminished Aβ accumulation, the proliferation of astrocytes, and cognitive defects in an in vivo AD model [44]. This evidence concerns the gene GSK3B and Alzheimer disease.